Bioxytran (OTCMKTS:BIXT – Get Free Report) issued its earnings results on Friday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.
Bioxytran Trading Down 5.2%
BIXT stock traded down $0.00 during mid-day trading on Friday, reaching $0.03. 4,000 shares of the stock traded hands, compared to its average volume of 83,667. Bioxytran has a 52-week low of $0.03 and a 52-week high of $0.17. The company has a market cap of $3.74 million, a P/E ratio of -1.65 and a beta of 1.95. The stock’s fifty day moving average is $0.04 and its 200-day moving average is $0.05.
About Bioxytran
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Read More
- Five stocks we like better than Bioxytran
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
